How long does Terbinafine stay in your system?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
In this brief article, we will discuss the approximate time taken by Terbinafine, an antifungal agent, to leave your system. We will also discuss various factors affecting the stay time or the duration of action of Terbinafine in the body.
How long does Terbinafine stay in your system?
Terbinafine can stay in your system for quite a while, with different parts of your body affecting how long it takes to completely eliminate the drug. The plasma half-life of Terbinafine is around 36 hours, meaning half of the drug is eliminated in that time (1,2).
The remaining drug further reduces to half of its concentration within the next 36 hours. Typically it takes five half-lives for a drug to completely wash out of your system, which indicates that Terbinafine should be removed within a week from your body.
However, Terbinafine has a tendency to stay in skin, nails, and adipose (fat) tissues for a longer period of time, making its terminal half-life much longer – up to 200 days. (2)
This is why even after you stop taking Terbinafine, it can still be detected in certain parts of your body for an extended period. It’s important to be aware of this when considering potential interactions with other medications and to follow your doctor’s advice for the safest use of the drug.
What factors can affect the time taken by Terbinafine to leave your body?
Several factors can influence how long Terbinafine stays in your body before it is completely eliminated. Some of these factors include (1,3):
- Dosage: The higher the dose of Terbinafine you take, the longer it may take for your body to clear the drug.
- Duration of use: If you have been taking Terbinafine for a prolonged period, it can take more time for the drug to leave your system completely.
- Age: Younger individuals may eliminate Terbinafine faster than older adults.
- Liver function: The liver plays a crucial role in breaking down and eliminating drugs from the body. If you have liver problems, it can slow down the clearance of Terbinafine.
- Kidney function: Similarly, impaired kidney function may affect how quickly your body can eliminate Terbinafine.
- Overall health: Your general health condition can impact how your body processes and eliminates the drug.
- Other medications: Certain medications can interact with Terbinafine, affecting its metabolism and elimination.
It’s important to talk to your healthcare provider about any concerns you may have regarding Terbinafine’s presence in your body and any potential interactions with other medications you might be taking.
It is also important to make sure that you’re Terbinafine in the best possible way while avoiding other medications and excessive consumption of alcohol – that may affect your antifungal treatment or your body’s natural ability to heal.
When does Terbinafine clearance hold clinical significance?
When it comes to Terbinafine clearance, two critical aspects that hold clinical significance are drug interactions and the duration of treatment.
Some drugs can affect Terbinafine metabolism, leading to altered clearance rates, which may necessitate dosage adjustments or close monitoring.
Additionally, the duration of treatment is essential in fungal infections treated with Terbinafine. Monitoring Terbinafine clearance helps healthcare providers determine the appropriate length of treatment needed for complete recovery (3).
If the drug stays in the body for an extended period, it can lead to drug accumulation, which may increase the risk of side effects and compromise the overall effectiveness of the treatment.
On the other hand, if the drug is cleared too quickly, it may not have sufficient time to combat the infection effectively.
Conclusion
In this article, we have discussed Terbinafine clearance and the factors that may affect it. We have also discussed the clinical significance of the time taken by Terbinafine to leave the body and when it can make a difference.
Was this helpful?
References
1.-
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 1549008, Terbinafine; [cited 2023 Aug. 1]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Terbinafine
2.-
Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441-72. doi: 10.2165/00003088-200140060-00005. PMID: 11475469. Available from: https://pubmed.ncbi.nlm.nih.gov/11475469/
3.-
Maxfield L, Preuss CV, Bermudez R. Terbinafine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31424802. https://www.ncbi.nlm.nih.gov/books/NBK545218
